YES1 and hepatocellular carcinoma: Our experimental data shows that the combination of YES1 inhibition (via siRNAs or dasatinib) with lenvatinib yields stronger antiproliferative effects than lenvatinib alone in HCC cells, which supports the notion of combination therapy as a promising strategy to overcome TKI resistance in the treatment of HCC in clinical settings.